Joe M. O'Sullivan
Queen's University Belfast
244 Papers
2.9K Citations
Joe M. O'Sullivan is an academic researcher from Queen's University Belfast. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 49, co-authored 219 publications. Previous affiliations of Joe M. O'Sullivan include The Royal Marsden NHS Foundation Trust & Belfast City Hospital.
Chat about Author
Papers
Showing all 244 results
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker,Sten Nilsson,Sten Nilsson,D. Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Mihalj Seke,Anders Widmark,D. C. Johannessen,Peter Hoskin,David Bottomley,Nicholas D. James,Arne Solberg,Isabel Syndikus,Ján Kliment,S. Wedel,S. Boehmer,Marcos F. Dall'Oglio,Lars Franzén,Robert E. Coleman,Nicholas J. Vogelzang,C.G. O'Bryan-Tear,K. Staudacher,J. Garcia-Vargas,M. Shan,Øyvind S. Bruland,Oliver Sartor +30 more
TL;DR: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival and was associated with low myelosuppression rates and fewer adverse events.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James,Nicholas D. James,Matthew R. Sydes,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Melissa R. Spears,Alastair W. S. Ritchie,Chris Parker,J. Martin Russell,Gerhardt Attard,Johann S. de Bono,William Cross,Robert Jones,George N. Thalmann,Claire Amos,David Matheson,Robin Millman,Mymoona Alzouebi,Sharon Beesley,Alison Birtle,Susannah Brock,Richard Cathomas,Prabir Chakraborti,Simon Chowdhury,Audrey Cook,Tony Elliott,Joanna Gale,Stephanie Gibbs,John Graham,J. Hetherington,Robert Hughes,Robert W. Laing,Fiona McKinna,Duncan McLaren,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Rajaguru Srinivasan,John Staffurth,Santhanam Sundar,Shaun Tolan,David Tsang,John Wagstaff,Mahesh K.B. Parmar +47 more
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
1.8K
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James,Johann S. de Bono,Melissa R. Spears,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Alastair W. S. Ritchie,Claire Amos,Clare Gilson,Robert Jones,David Matheson,Robin Millman,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Chris Parker,J. Martin Russell,Dominik Berthold,Chris Brawley,Fawzi Adab,San Aung,Alison Birtle,Jo Bowen,Susannah Brock,Prabir Chakraborti,C.L. Ferguson,Joanna Gale,Emma Gray,Mohan Hingorani,Peter Hoskin,Jason F. Lester,Zafar Malik,Fiona McKinna,Neil McPhail,Julian Money-Kyrle,Joe M. O'Sullivan,Omi Parikh,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Carys Thomas,John Wagstaff,James D. Wylie,Anjali Zarkar,Mahesh K.B. Parmar,Matthew R. Sydes +46 more
TL;DR: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
TL;DR: Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer after 5 years follow-up.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Chris Parker,Nicholas D. James,Christopher D. Brawley,Noel W. Clarke,Alex Hoyle,Adnan Ali,A.W.S. Ritchie,Gerhardt Attard,Simon Chowdhury,William Cross,David P. Dearnaley,Silke Gillessen,Silke Gillessen,Clare Gilson,Robert Jones,Ruth E Langley,Zafar Malik,Malcolm David Mason,David Matheson,Robin Millman,J. Martin Russell,George N. Thalmann,Claire Amos,Roberto Alonzi,Amit Bahl,Alison Birtle,O.S. Din,Hassan Douis,C. Eswar,Joanna Gale,Melissa Gannon,Sai Jonnada,S. Khaksar,Jason F. Lester,Joe M. O'Sullivan,Omi Parikh,Ian Pedley,Delia Pudney,D. Sheehan,Narayanan Srihari,Anna T.H. Tran,Mahesh K.B. Parmar,Matthew R. Sydes +42 more
TL;DR: Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer, and the benefit would be greatest in patients with a low metastatic burden.
1K